Should I buy or sell Intra-Cellular Therapies stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ITCI shares. View ITCI analyst ratings or view top-rated stocks .

What is Intra-Cellular Therapies' stock price target for 2024?

10 brokerages have issued 12-month price objectives for Intra-Cellular Therapies' shares. Their ITCI share price targets range from $62.00 to $101.00. On average, they anticipate the company's stock price to reach $81.42 in the next twelve months. This suggests a possible upside of 1.1% from the stock's current price. View analysts price targets for ITCI or view top-rated stocks among Wall Street analysts .

How have ITCI shares performed in 2024?

Intra-Cellular Therapies' stock was trading at $71.62 at the beginning of 2024. Since then, ITCI stock has increased by 12.4% and is now trading at $80.51. View the best growth stocks for 2024 here .

When is Intra-Cellular Therapies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our ITCI earnings forecast .

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) announced its quarterly earnings results on Thursday, February, 22nd. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.14. The biopharmaceutical company earned $132.10 million during the quarter, compared to the consensus estimate of $135.97 million. Intra-Cellular Therapies had a negative net margin of 30.08% and a negative trailing twelve-month return on equity of 23.02%. The company's revenue for the quarter was up 50.3% on a year-over-year basis. During the same period in the prior year, the business earned ($0.45) EPS.

What ETFs hold Intra-Cellular Therapies' stock?

ETFs with the largest weight of Intra-Cellular Therapies (NASDAQ:ITCI) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) , AdvisorShares Psychedelics ETF (PSIL) , Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) , iShares Neuroscience and Healthcare ETF (IBRN) , Invesco Biotechnology & Genome ETF (PBE) , iShares U.S. Pharmaceuticals ETF (IHE) , Virtus LifeSci Biotech Products ETF (BBP) and Principal Healthcare Innovators ETF (BTEC) .

What other stocks do shareholders of Intra-Cellular Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE) , Amarin (AMRN) , Gilead Sciences (GILD) , CRISPR Therapeutics (CRSP) , Synergy Pharmaceuticals (SGYP) , Myovant Sciences (MYOV) , Novavax (NVAX) , Pfizer (PFE) , AbbVie (ABBV) and Clovis Oncology (CLVS) .

Who are Intra-Cellular Therapies' major shareholders?

Intra-Cellular Therapies' stock is owned by many different retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.02%) and First Hawaiian Bank (0.01%). Insiders that own company stock include Christopher D Alafi, Christopher D Alafi , Joel S Marcus , Lawrence J Hineline, Lawrence J Hineline , Mark Neumann , Michael Halstead , Nostrand Robert L Van , Rory B Riggs , Sharon Mates , Suresh K Durgam and Suresh K Durgam . View institutional ownership trends .

How do I buy shares of Intra-Cellular Therapies?

Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

NASDAQ:ITCI

Intra-Cellular Therapies (ITCI) Stock Price, News & Analysis

→ Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad)

Free ITCI Stock Alerts

Notice: Trading of Intra-Cellular Therapies halted at 06:55 AM EST due to "News pending".

$81.01

+16.25 (+25.09%)

(As of 02:11 PM ET)

Compare

Today's Range: $75.00
▼
$84.89
50-Day Range: $64.37
▼
$75.65
52-Week Range: $45.50
▼
$84.89

Volume: 5.78 million shs
Average Volume: 816,843 shs
Market Capitalization: $7.84 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $81.42

Get Intra-Cellular Therapies alerts:

Intra-Cellular Therapies MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.90 Rating Score
Upside/Downside: 1.1% Upside
$81.42 Price Target
Short Interest: Bearish
3.58% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.23
Upright™ Environmental Score
News Sentiment: 0.43
Based on 20 Articles This Week
Insider Trading: Selling Shares
$20.86 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.64) to $0.92 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.45 out of 5 stars

Medical Sector

101st out of 930 stocks

Pharmaceutical Preparations Industry

32nd out of 430 stocks

2.5

Analyst's Opinion

Consensus Rating
Intra-Cellular Therapies has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Intra-Cellular Therapies has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
3.58% of the outstanding shares of Intra-Cellular Therapies have been sold short.
Short Interest Ratio / Days to Cover
Intra-Cellular Therapies has a short interest ratio ("days to cover") of 4.5.
Change versus previous month
Short interest in Intra-Cellular Therapies has recently increased by 4.83%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Intra-Cellular Therapies does not currently pay a dividend.
Dividend Growth
Intra-Cellular Therapies does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Intra-Cellular Therapies has received a 69.69% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is mostly driven by its "Antipsychotics", "Clinical research services for mood disorders", and "Clinical research services for substance abuse disorders " products. See details.
Environmental Sustainability
The Environmental Impact score for Intra-Cellular Therapies is -1.23.

2.5

News and Social Media Coverage

News Sentiment
Intra-Cellular Therapies has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 20 news articles for Intra-Cellular Therapies this week, compared to 4 articles on an average week.
Search Interest
7 people have searched for ITCI on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.
MarketBeat Follows
Only 7 people have added Intra-Cellular Therapies to their MarketBeat watchlist in the last 30 days. This is a decrease of -22% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Intra-Cellular Therapies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $20,860,487.00 in company stock.
Percentage Held by Insiders
Only 3.40% of the stock of Intra-Cellular Therapies is held by insiders.
Percentage Held by Institutions
92.33% of the stock of Intra-Cellular Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($0.64) to $0.92 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Intra-Cellular Therapies is -55.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Intra-Cellular Therapies is -55.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Intra-Cellular Therapies has a P/B Ratio of 13.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Manward Press

Can't believe it's happening again

One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.

We explain how this event works in full right here.

About Intra-Cellular Therapies Stock (NASDAQ:ITCI)

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

ITCI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ITCI Stock News Headlines

April 16, 2024 | seekingalpha.com

Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data

April 16, 2024 | marketwatch.com

Intra-Cellular Therapies Discloses Positive Study Results for Depression Treatment

April 16, 2024 | Gold Safe Exchange (Ad)

Trump’s “Tax Free” Retirement Strategy

Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.

April 16, 2024 | marketwatch.com

Intra-Cellular Therapies Shares Rise on Lumateperone Study Results

April 16, 2024 | markets.businessinsider.com

Why Intra-Cellular Therapies Is Rising In Pre-market?

April 16, 2024 | finance.yahoo.com

Intra-Cellular Therapies Stock Launches 20% Into Breakout Territory On Depression Test Results

April 16, 2024 | globenewswire.com

Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

April 15, 2024 | nasdaq.com

ITCI Quantitative Stock Analysis

April 16, 2024 | Gold Safe Exchange (Ad)

Trump’s “Tax Free” Retirement Strategy

April 14, 2024 | americanbankingnews.com

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Given Average Rating of "Moderate Buy" by Analysts

April 13, 2024 | americanbankingnews.com

Q1 2024 EPS Estimates for Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Lowered by Analyst

April 6, 2024 | americanbankingnews.com

Intra-Cellular Therapies (NASDAQ:ITCI) Given "Buy" Rating at Needham & Company LLC

April 3, 2024 | benzinga.com

8 Analysts Assess Intra-Cellular Therapies: What You Need To Know

April 3, 2024 | markets.businessinsider.com

Intra-Cellular Therapies: A Strong Buy on Patent Defense and Promising Clinical Prospects

March 24, 2024 | finance.yahoo.com

Intra-Cellular Therapies (NASDAQ:ITCI) advances 6.5% this week, taking five-year gains to 467%

March 21, 2024 | markets.businessinsider.com

Buy Rating Affirmed on Intra-Cellular Therapies Ahead of Key Phase 3 Results and Strategic Leadership Enhancements

March 19, 2024 | finanznachrichten.de

Intra-Cellular Therapies Inc.: Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes

March 19, 2024 | msn.com

Intra-Cellular Therapies promotes Michael Halstead to President

March 19, 2024 | globenewswire.com

Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes

March 16, 2024 | ca.finance.yahoo.com

ITCI Apr 2024 90.000 call

March 12, 2024 | finance.yahoo.com

Intra-Cellular Therapies Inc Chairman, President & CEO Sharon Mates Sells 61,277 Shares

March 7, 2024 | finance.yahoo.com

ITCI Aug 2024 50.000 call

March 6, 2024 | globenewswire.com

Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences

March 5, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Intra-Cellular Therapies Amid Positive Outlook for Caplyta’s MDD Trial

February 28, 2024 | finance.yahoo.com

EVP and General Counsel Michael Halstead Sells Shares of Intra-Cellular Therapies Inc

February 27, 2024 | globenewswire.com

Intra-Cellular Therapies to Present at the 44th Annual TD Cowen Health Care Conference

February 26, 2024 | markets.businessinsider.com

Optimistic Buy Rating for Intra-Cellular Therapies Amid Growth and Operational Efficiency

See More Headlines

Receive ITCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/22/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ITCI
CUSIP: N/A
CIK: 1567514
Web: www.intracellulartherapies.com
Phone: (464) 440-9333
Fax: 646-440-9334
Employees: 610
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $81.42
High Stock Price Target: $101.00
Low Stock Price Target: $62.00
Potential Upside/Downside: +25.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.90
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.46)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-139,670,000.00
Net Margins: -30.08%
Pretax Margin: -29.94%
Return on Equity: -23.02%
Return on Assets: -19.39%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.41
Quick Ratio: 5.31

Sales & Book Value

Annual Sales: $464.37 million
Price / Sales: 13.50
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.15 per share
Price / Book: 10.53

Miscellaneous

Outstanding Shares: 96,810,000
Free Float: 93,516,000
Market Cap: $6.27 billion
Optionable: Optionable
Beta: 1.02

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Dr. Sharon Mates Ph.D. (Age 71)
Co-Founder, Chairman & CEO
Comp: $2.23M
Mr. Michael I. Halstead J.D. (Age 51)
President
Comp: $983.65k
Dr. Suresh K. Durgam M.D. (Age 55)
Executive VP & Chief Medical Officer
Comp: $961.84k
Mr. Mark Neumann (Age 61)
EVP & Chief Commercial Officer
Comp: $998.36k
Dr. Robert E. Davis Ph.D. (Age 73)
Senior VP & Chief Scientific Officer
Comp: $646.12k
Mr. Juan Fernando Sanchez (Age 53)
Vice President of Corporate Communications & Investor Relations
Comp: $296.75k
Ms. Karen Patruno Sheehy Esq. (Age 62)
Senior VP & Chief Compliance Officer
Dr. Michael Olchaskey
Senior VP & Head of Regulatory Affairs
Mr. John A. Bardi
Senior VP of Market Access, Policy & Government Affairs
Dr. Willie R. Earley M.D.
Senior VP & Head of Clinical Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ITCI Stock Analysis - Frequently Asked Questions

Should I buy or sell Intra-Cellular Therapies stock right now?: 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ITCI shares.
View ITCI analyst ratings or view top-rated stocks.
What is Intra-Cellular Therapies' stock price target for 2024?: 10 brokerages have issued 12-month price objectives for Intra-Cellular Therapies' shares. Their ITCI share price targets range from $62.00 to $101.00. On average, they anticipate the company's stock price to reach $81.42 in the next twelve months. This suggests a possible upside of 1.1% from the stock's current price.
View analysts price targets for ITCI or view top-rated stocks among Wall Street analysts.
How have ITCI shares performed in 2024?: Intra-Cellular Therapies' stock was trading at $71.62 at the beginning of 2024. Since then, ITCI stock has increased by 12.4% and is now trading at $80.51.
View the best growth stocks for 2024 here.
When is Intra-Cellular Therapies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ITCI earnings forecast.
How were Intra-Cellular Therapies' earnings last quarter?: Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) announced its quarterly earnings results on Thursday, February, 22nd. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.14. The biopharmaceutical company earned $132.10 million during the quarter, compared to the consensus estimate of $135.97 million. Intra-Cellular Therapies had a negative net margin of 30.08% and a negative trailing twelve-month return on equity of 23.02%. The company's revenue for the quarter was up 50.3% on a year-over-year basis. During the same period in the prior year, the business earned ($0.45) EPS.

What ETFs hold Intra-Cellular Therapies' stock?: ETFs with the largest weight of Intra-Cellular Therapies (NASDAQ:ITCI) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), AdvisorShares Psychedelics ETF (PSIL), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), iShares Neuroscience and Healthcare ETF (IBRN), Invesco Biotechnology & Genome ETF (PBE), iShares U.S. Pharmaceuticals ETF (IHE), Virtus LifeSci Biotech Products ETF (BBP) and Principal Healthcare Innovators ETF (BTEC).
What other stocks do shareholders of Intra-Cellular Therapies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS).
Who are Intra-Cellular Therapies' major shareholders?: Intra-Cellular Therapies' stock is owned by many different retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.02%) and First Hawaiian Bank (0.01%). Insiders that own company stock include Christopher D Alafi, Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Lawrence J Hineline, Mark Neumann, Michael Halstead, Nostrand Robert L Van, Rory B Riggs, Sharon Mates, Suresh K Durgam and Suresh K Durgam.
View institutional ownership trends.
How do I buy shares of Intra-Cellular Therapies?: Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ITCI) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Intra-Cellular Therapies (ITCI) Stock Price, News & Analysis

Intra-Cellular Therapies MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Intra-Cellular Therapies Stock (NASDAQ:ITCI)

ITCI Stock Price History

ITCI Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ITCI Stock Analysis - Frequently Asked Questions

Overall MarketRank^™